Although somatic cell activation of the embryonic stem cell (ESC) pluripotency factor OCT4 has been reported, this previous work has been controversial and has not demonstrated a functional role for OCT4 in somatic cells. Here we demonstrate that smooth muscle cell (SMC)-specific conditional knockout of Oct4 in Apoe −/− mice resulted in increased lesion size and changes in lesion composition that are consistent with decreased plaque stability, including a thinner fibrous cap, increased necrotic core area, and increased intraplaque hemorrhage. Results of SMC-lineage-tracing studies showed that these effects were probably the result of marked reductions in SMC numbers within lesions and SMC investment within the fibrous cap, which may result from impaired SMC migration. The reactivation of Oct4 within SMCs was associated with hydroxymethylation of the Oct4 promoter and was hypoxia inducible factor-1 (HIF-1, encoded by HIF1A) and Krüppel-like factor-4 (KLF4)-dependent. These results provide the first direct evidence that OCT4 has a functional role in somatic cells, and they highlight the potential role of OCT4 in normal and diseased somatic cells. npg
Octamer-binding transcriptional factor 4 (Oct4, also known as POu5f1) 1 plays a crucial part in regulating pluripotency in ESCs, and it has been considered to be permanently epigenetically silenced in adult somatic cells 2 . Recent evidence suggests that Oct4 may be reactivated in cultured pulmonary artery SMCs that are exposed to chronic hypoxia 3 , in tumor cells 4, 5 and in certain other somatic cell types 6 , but this evidence is highly controversial (reviewed in ref. 2) because of potential experimental confounders: possible antibody cross-reactivity with other OCT4 isoforms that do not regulate ESC pluripotency 7, 8 , the detection of Oct4 pseudogenes, low OCT4 expression levels 9, 10 , and a lack of appropriate controls (for example, Oct4-genetic-knockout cells). Importantly, no evidence exists for a functional role of OCT4 within any of the somatic cell types in which Oct4 expression has been detected. Indeed, conditional Oct4-knockout mice show no functional defects or alterations in tissue regeneration after skin injury, partial hepatectomy, irradiation exposure, or bone marrow transplantation 6 . As such, the most conservative and authoritative data at this time indicate that Oct4 is nonfunctional in adult somatic cells and is dispensable for the proliferation and phenotypic transitions of somatic cells. Consistent with the idea that OCT4 may be exclusively expressed and have functional effects within ESCs, OCT4 (together with KLF4, SRY-box 2 (SOX2) and c-MYC) is required for the reprogramming of somatic cells into induced pluripotent stem cells (iPSCs) 11 , although it was subsequently shown that OCT4 can be replaced by other reprogramming factors that activate OCT4 (refs. [12] [13] [14] .
We and others have previously shown that after vascular injury or during the development of atherosclerosis, vascular SMCs undergo de-differentiation, also known as phenotypic switching. This process is characterized by a loss of expression of SMC-specific marker genes, such as Acta2, Myh11, tagln, and cnn1, and is coincident with increased cell proliferation, migration, and extracellular matrix (ECM) production (reviewed in ref. 15 ). It is thought to have evolved to enable mature blood vessels to undergo repair and remodeling. However, this process has also been postulated to have a crucial role in a number of major human diseases, including atherosclerosis, hypertension, asthma, tumor angiogenesis and metastasis, and aneurysms [15] [16] [17] . Indeed, recent SMC lineage-tracing and conditional Klf4-knockout studies from our lab 18 have demonstrated that SMCs have a much greater role in lesion pathogenesis than has generally been recognized. For example, we showed that previous studies have grossly underestimated the number of SMC-derived lesional cells: >80% of SMCs within advanced atherosclerotic lesions of apolipoprotein E-deficient (Apoe −/− ) mice lacked detectable expression of SMC differentiation markers such as ACTA2, and they expressed markers of other cell types, including macrophages and mesenchymal stem cells. In addition, we showed that SMC-specific conditional knockout of the stem cell pluripotency factor Klf4 results in a decrease in lesion size of >50% and increases in indices of plaque stability, as compared to Klf4 +/+ mice. Notably, loss of Klf4 within SMCs did not inhibit SMC phenotypic switching; the overall number of lesional SMCs was unaltered. However, loss of Klf4 seemed to promote the transition of SMCs from an athero promoting pro-inflammatory foam cell state to an athero protective state. Here we show that the essential iPS/ESC pluripotency factor OCT4 also has a crucial role in the regulation of the phenotypic transition of SMCs during atherosclerosis. In complete contrast to the effects of SMC-specific conditional knockout of Klf4, however, loss of Oct4 in SMCs resulted in marked increases in lesion size, as well as marked decreases in multiple indices of plaque stability as compared to Oct4 +/+ mice, probably owing to markedly impaired investment of SMCs into the lesion and the fibrous cap.
RESULTS

OCT4 is activated within mouse and human atherosclerotic lesions
To determine whether the pluripotency factor OCT4 can be reactivated in diseased blood vessels, we used Oct4-IRES-GfP reporter mice, which express GfP under the control of an internal ribosomal entry site (IRES) downstream of the Oct4 gene ( Supplementary  Fig. 1a ) 6 , and we crossed these with Apoe −/− mice 19 . Notably, this approach avoids potential pitfalls of detecting OCT4 pseudogene expression or OCT4 antibody cross-reactivity. We observed a marked increase in GfP mRNA expression within atherosclerotic brachiocephalic arteries (BCAs) of Oct4-IRES-GfP +/+ Apoe −/− mice after 10 and 18 weeks of high-fat, Western-diet feeding (Fig. 1a) . This increase in GfP expression did not occur in chow-fed Oct4-IRES-GfP +/+ Apoe +/+ control mice (Fig. 1a) , and was accompanied by increased GFP protein expression ( Fig. 1b) .
To avoid potential pitfalls in the detection of OCT4 isoforms 20 and to test the hypothesis that OCT4 has a functional role in the regulation of SMC phenotypic transitions in vivo, we generated Apoe −/− SMCspecific, conditional-Oct4-knockout mice by crossing Oct4 flox/flox mice 6, 21 with Apoe −/− mice and mice carrying a tamoxifen-inducible Cre-recombinase under the control of the SMC-specific Myh11 promoter enhancer (Myh11-CreER T2 ) 22 (Supplementary Fig. 1b ). Tamoxifen-treated Oct4 flox/flox ;Myh11-CreER T2 mice (designated SMC Oct4 ∆/∆ mice) demonstrated a high efficiency of Oct4 recombination in SMC-rich tissues such as the aorta and femoral artery; the frequency of recombination, when corrected for the fraction of SMCs, was estimated to be >95% ( Supplementary Fig. 1c,d) . By contrast, there was no detectable recombination in non-SMC-rich tissues, such as the liver (Supplementary Fig. 1c ). After 18 weeks of Western-diet feeding, SMC Oct4 ∆/∆ Apoe −/− mice exhibited no significant differences, as compared to control SMC Oct4 +/+ Apoe −/− mice, in cholesterol or triglyceride levels or body weight, or in heart, lung and spleen weights relative to body weight ( Supplementary Fig. 1e ).
Immunostaining with an antibody specific to the 'pluripotent' isoform of OCT4 (OCT4A) 20 showed that OCT4 expression was markedly induced in atherosclerotic lesions, as well as in medial and adventitial cells, in the BCAs of SMC Oct4 +/+ Apoe −/− mice after 18 weeks of Western-diet feeding (Supplementary Fig. 1f ). To determine whether OCT4 is expressed within SMCs or SMC-derived cells within lesions, we performed immunofluorescence staining of advanced atherosclerotic lesions from the BCAs of Western-diet-fed, Apoe −/− SMC-lineagetracing mice, which harbor an SMC-specific, conditional eYFP allele npg (designated as SMC YfP +/+ Apoe −/− mice), as previously described 23 . Notably, we found that OCT4 was expressed by YFP + ACTA2 − cells in both the medial layer and the lesion, as well as by YFP + ACTA2 + cells in the medial layer ( Supplementary Fig. 2a ). SMC YfP +/+ Oct4 ∆/∆ Apoe −/− mice showed a significant reduction (P < 0.05) in the frequency of OCT4 + YFP + medial cells within BCA lesions after 18 weeks of Western-diet feeding, as compared to SMC YfP +/+ Oct4 +/+ Apoe −/− control mice (Supplementary Fig. 2b) . However, the fraction of OCT4 + YFP + cells in lesions of Oct4-knockout mice was approximately 20% at this time point, as compared to <5% (i.e., >95% recombination) at 3 weeks after the final tamoxifen injection ( Supplementary  Fig. 1d ), which suggests that the small fraction of SMCs that did not undergo loss of Oct4 subsequently showed selective survival and/or proliferation during the progression of atherosclerosis.
To determine whether OCT4 is also activated within human advanced atherosclerotic lesions, we performed high-resolution confocal-microscopic analyses of advanced human coronary artery lesions stained with an antibody specific for the 'pluripotent' OCT4 isoform, as well as with an antibody for ACTA2 and with DAPI ( Supplementary Fig. 2c,d) . We examined multiple sections of coronary arteries from 16 different human subjects who had atherosclerotic lesions of varying severity (seven samples with <20% occlusion; nine samples with >80% occlusion). Given this small sample size and unknown variables, including age and gender, it is not possible to make definitive statements regarding relative frequencies, or to relate OCT4 expression levels to plaque stage according to American Heart Association criteria 24 . However, numerous OCT4 + cells were present throughout severe lesions and the underlying media, but these were rare in samples with few or no atherosclerotic lesions ( Supplementary  Fig. 2d ). Given ambiguities in using ACTA2 to identify SMCs within lesions, we are unable to rigorously ascertain the origin of these OCT4 + cells. However, taken together with the results from the SMC-lineage-tracing mice, it is likely that at least some of the OCT4 + cells observed in the human lesions are SMC derived. Unfortunately, attempts to identify SMCs using our in situ hybridization proximity ligation assay (ISH-PLA) method 23 were unsuccessful, owing to incompatibility of this method with the OCT4 antibody.
Loss of Oct4 in SMCs is detrimental for plaque pathogenesis SMC Oct4 ∆/∆ Apoe −/− mice exhibited large increases in BCA lesion size ( Fig. 1c,d) , area within the external elastic lamina (EEL) (Fig. 1e) , and area within the internal elastic lamina (IEL) ( Fig. 1f) , as well as reduced lumen size ( Fig. 1g) , as compared to SMC Oct4 +/+ Apoe −/− littermate control mice. Moreover, SMC-specific knockout of Oct4 was associated with increases in multiple indices of plaque instability, including increased necrotic core area ( Fig. 2a) , decreased cell 
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Antigen processing and presentation Leukocyte transendothelial migration Prion diseases Systemic lupus erythematosus density in non-necrotic lesion areas ( Fig. 2b) , increased lipid accumulation, as assessed by Oil Red O staining ( Fig. 2c,d) , and increased intraplaque hemorrhage, as assessed by TER119 staining (Fig. 2e,f) . Moreover, whereas there was no difference between SMC Oct4 ∆/∆ Apoe −/− mice and their littermate controls in total collagen content within the lesion or the tunica media ( Supplementary Fig. 3a-c) , there was decreased collagen maturation, as measured through PicroSirius Red staining ( Supplementary Fig. 3d-f ).
To elucidate potential mechanisms by which the loss of Oct4 within SMCs results in lesions that are larger than those in wild-type control littermate mice and that exhibit features of reduced stability, we performed RNA-seq analyses on mRNA extracted from the BCA regions of SMC YfP +/+ Oct4 +/+ Apoe −/− mice and SMC YfP +/+ Oct4 ∆/∆ Apoe −/− mice fed a Western diet for 18 weeks. We found significant (P adj ≤ 0.05) upregulation of gene pathways associated with antigen processing; complement activation and coagulation; and leucocyte transendothelial migration signaling in SMC YfP +/+ Oct4 ∆/∆ Apoe −/− mice, as compared to control SMC YfP +/+ Oct4 +/+ Apoe −/− mice ( Fig. 2g and Supplementary Table 1 ). Conversely, SMC YfP +/+ Oct4 ∆/ ∆ Apoe −/− mice showed downregulation of several pathways that possibly contribute to plaque destabilization, including ECM-receptor interaction and focal adhesion, as compared to control mice ( Fig. 2h and Supplementary Table 1) . Notably, the samples used in these RNA-seq analyses contain many different cell types; thus, we cannot directly ascertain which genes exhibit OCT4-dependent expression in SMCs versus secondary changes in expression in non-SMC cell types.
To provide unambiguous identification of SMC-derived cells within atherosclerotic lesions and to determine the mechanisms by which the loss of Oct4 in SMCs alters plaque pathogenesis, we performed high-resolution z-stack confocal immunofluorescence analyses of BCA lesions within Oct4 +/+ and Oct4 ∆/∆ Apoe −/− SMClineage-tracing mice. Notably, we observed a marked decrease in the number of SMC-derived (YFP + ) cells within lesions of SMC YfP +/+ Oct4 ∆/∆ ApoE −/− mice versus control SMC YfP +/+ Oct4 +/+ Apoe −/− mice ( Fig. 3a,b) , including a >50% reduction in the number of YFP + , MYH11 + ACTA2 + YFP + and ACTA2 + YFP + cells within the area encompassing the inner 30-µm layer of the fibrous cap overlying lesions (designated as the 30-µm fibrous cap area) ( Fig. 3c,d) . No difference between YFP + , MYH11 + ACTA2 + YFP + cell and ACTA2 + YFP + cell composition was observed within the tunica media ( Supplementary  Fig. 4) . Surprisingly, although the loss of Oct4 in SMCs inhibited the migration of cells into lesions, it did not prevent them from transitioning to ber of YFP + LGALS3 + cells within the media (Fig. 3e) , but not the intima (Fig. 3f) , of SMC YfP +/+ Oct4 ∆/∆ Apoe −/− mice, as compared to control mice.
Taken together, these results indicate that the loss of Oct4 within SMCs leads to a marked reduction in the number of SMC-derived (YFP + ) cells within lesions, including within the fibrous cap. Paradoxically, this was associated with an increase in overall lesion size as a result of large increases in the amounts of multiple noncellular components of the lesion, including lipids, hemorrhagic products, and necrotic tissue.
Loss of Oct4 in LysM + cells does not alter plaque pathogenesis
To test whether OCT4 also has a functional role in myeloid cells during the development of atherosclerosis, we generated Apoe −/− myeloid-selective, Oct4-knockout mice by crossing Oct4 flox/flox mice with LysM-Cre;ROSA26-Stop flox eYfP +/+ Apoe −/− mice (LysM Cre/Cre YfP +/+ Apoe −/− ) 18, 25 . LysM-Cre has previously been shown to mediate recombination in several myeloidderived lineages, including macrophages (83-98%), granulocytes (100%) and CD11c + splenic dendritic cells (16%) 25 .
LysM Cre/Cre YfP +/+ Oct4 ∆/∆ Apoe −/− mice exhibited no significant differences in body weights, tissue weights, cholesterol levels, triglyceride npg levels (Supplementary Fig. 1e ) or blood cell counts ( Supplementary  Fig. 5a) , as compared to LysM Cre/Cre YfP +/+ Oct4 +/+ Apoe −/− control mice, after 18 weeks of Western diet feeding. In addition, the loss of Oct4 in myeloid cells had no effect on lesion size (Supplementary Fig. 5b,c) or lumen or EEL areas (data not shown), as compared to control LysM Cre/Cre YfP +/+ Oct4 +/+ Apoe −/− mice. As observed in atherosclerotic lesions in BCAs, there were also no differences in the number of YFP + LGALS3 + cells or in the overall numbers of YFP + cells or lectin, galactose binding, soluble-3-positive (LGALS3 + ) cells between these two groups (Supplementary Fig. 5b,d) . Notably, the only difference that we observed was a significant decrease in the overall number of YFP + cells (P < 0.05), including those that were LGALS3 + (P < 0.01) or ACTA2 + (P < 0.01), in the 30-µm fibrous cap area of lesions in LysM Cre/Cre YfP +/+ Oct4 ∆/∆ Apoe −/− mice, as compared to control mice (Supplementary Fig. 5e ). In addition, we observed that most YFP + OCT4 + or YFP + ACTA2 + OCT4 + cells in LysM Cre/Cre YfP +/+ Oct4 +/+ Apoe −/− mice were found within the 30-µm fibrous cap area (Supplementary Fig. 5f ). The effects of LysM-Cre-mediated Oct4 knockout might be due to Oct4 deficiency in phenotypically modulated SMCs, rather than in myeloid cells, because it is possible that a subset of SMC-derived, macrophage-like cells within lesions activate LysM-Cre and lose Oct4 expression after they have migrated into the lesion, but before they migrate into the fibrous cap.
Loss of Oct4 results in impaired SMC migration
We next tested whether the decrease in the number of SMCs within lesions of SMC YfP +/+ Oct4 ∆/∆ ApoE −/− mice was a result of increased apoptosis, reduced proliferation, and/or reduced migration. We observed no changes in the frequency of either YFP + CASP3 + cells ( Fig. 4a and Supplementary Fig. 6a,b) or YFP + MKI67 + cells ( Fig. 4b and Supplementary Fig. 6c,d) between SMC YfP +/+ Oct4 ∆/∆ ApoE −/− and SMC YfP +/+ Oct4 +/+ ApoE −/− mice, which indicates that reduced numbers of SMC-derived cells in lesions were not the result of changes in SMC apoptosis or proliferation, and suggests that the loss of Oct4 may result in impaired migration. Given that it is not possible to directly access SMC migration during the development of advanced lesions in vivo, we tested the effect of Oct4 knockout on the proliferation and migration of cultured SMCs treated with pro-atherogenic oxidized phospholipids 26, 27 . Aortic SMCs isolated from Oct4 +/+ mice demonstrated a greater than threefold increase in Oct4 mRNA expression in response to the oxidized phospholipid POVPC (1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine) and oxidized low density lipoprotein (oxLDL), but not to a nonoxidized form of LDL, as compared to vehicle-treated control (Supplementary Fig. 7a) . These effects were nearly completely abrogated in Oct4 ∆/∆ SMCs. Oct4 ∆/∆ SMCs failed to migrate in response to POVPC (Fig. 4c) . The effects of genetic inactivation of Oct4 on the proliferation of cultured SMCs were small, and they varied as a function of experimental conditions, with modest increases in cell number observed for SMCs grown in 2% serum, but no effect on POVPCinduced proliferation (Supplementary Fig. 7b) . Conversely, lentivirus-mediated overexpression of OCT4 decreased the proliferation but increased the migration of SMCs, as compared to control lentivirusinfected cells (Supplementary Fig. 7c-e ). Taken together, these results indicate that SMC migration, at least in vitro, is OCT4 dependent.
To determine whether the knockout of Oct4 also inhibits SMC migration within intact arteries, we studied SMC outgrowth ex vivo from aortic explants from SMC YfP +/+ Oct4 +/+ Apoe −/− mice and SMC YfP +/+ Oct4 ∆/∆ Apoe −/− mice. There was a complete lack of migration of YFP + SMCs cells from Oct4 ∆/∆ aortic explants (Fig. 4d) . 
Loss of Oct4 in SMCs results in suppression of migrationrelated genes
We next sought to determine whether OCT4 directly regulates genes that are associated with migration. Multiple ECM-related genes required for SMC migration, including collagens col5a2, col6a2 and col15a1, as well as tissue inhibitor of matrix metalloproteinase 1 (timp1) and osteopontin (Opn), were upregulated in Oct4 +/+ SMCs but not in Oct4 ∆/∆ SMCs in response to POVPC (Supplementary Fig. 8) . It was previously shown that the Opn gene is transcriptionally activated by OCT4 in pre-implantation mouse embryos and cultured pluripotent cells 28 . Oct4 ∆/∆ SMCs also exhibited markedly reduced expression and activity of the matrix metalloproteinases MMP3 and MMP13 ( Fig. 4e-h) , which have previously been shown to be important for SMC migration 29, 30 . To more directly assess which genes are regulated by OCT4 in SMCs, we performed RNA-seq analyses in cultured SMCs treated with POVPC under normoxic or hypoxic conditions (1% O 2 ) and compared these results with the in vivo RNA-seq data obtained from BCA regions (Fig. 2g,h) . Hypoxia is well known to have a key role in the maintenance of Oct4 expression within stem cell niches 31 , and it also has been implicated in atherosclerosis 32 . Moreover, the exposure of pulmonary arterial SMCs to hypoxia was claimed to result in the activation of OCT4 (ref.
3), although no evidence was presented to suggest that this had functional consequences. We found that exposing cultured SMCs to hypoxia resulted in the transcriptional activation of Oct4 and the downregulation of Acta2 (Supplementary Fig. 9a ). Comparative analysis of the in vitro and in vivo RNA-seq data sets revealed 17 genes that exhibited similar changes in both Oct4 ∆/∆ cultured SMCs and SMC YfP +/+ Oct4 ∆/∆ Apoe −/− atherosclerotic lesions, as compared to Oct4 wildtype controls (Supplementary Fig. 9b and Supplementary Table 2) . Notably, the majority of downregulated genes, including Limch1, Slit3, Kcnd3, Sorl1, cacna1c, cap2 and Lgr6, are known to be crucial in regulating cell migration (Supplementary Table 2) , a finding that is consistent with the data showing that Oct4 knockout virtually abolishes the migration of SMCs both in vitro and within intact tissue specimens.
Taken together, our results suggest that the primary mechanism responsible for the decrease in SMC-derived (YFP + ) cells within lesions of SMC YfP +/+ Oct4 ∆/∆ Apoe −/− mice is impaired migration of SMCs from the media into the intima, resulting in part from the failure of cells to activate the expression of ECM proteins and other proteins that are required for migration. However, we cannot rule out the possibility that alterations in SMC proliferation or apoptosis at earlier time points may also contribute to this phenotype.
Epigenetic and transcriptional mechanisms of Oct4 activation
The Oct4 proximal and distal promoters are epigenetically silenced during the differentiation of ESCs into somatic cells through stable DNA methylation 33, 34 . Similarly, we found that the differentiation of SMC precursor cells (A404 cells) 35 into mature SMCs was associated with a marked increase in DNA methylation of the Oct4 locus, a decrease in Oct4 expression, and a concomitant activation of multiple SMC differentiation marker genes, as compared to undifferentiated A404 cells (Supplementary Fig. 10 ). In addition, the knockdown of Oct4 in SMC precursors was sufficient to initiate the SMC differentiation program in these cells (Supplementary Fig. 10c ). However, we found no evidence that hypoxia-and/or POVPC-induced activation of Oct4 was associated with a reduction in DNA methylation of the Oct4 promoter, as assessed by bisulfite sequencing; in fact, hypoxia treatment resulted in a slight increase in methylcytosine levels relative to those in normoxic conditions (Fig. 5a) .
The reactivation of Oct4 during iPSC reprogramming by the DNA hydroxylase TET1 through hydroxymethylation of methylated cytosines has recently been reported 14 . We thus postulated that the reactivation of Oct4 within vascular SMCs might occur through Figure 5 Activation of the Oct4 promoter in vitro and in vivo is associated with increased hydroxymethylation. (a) Bisulfite-sequencing analysis of the Oct4 promoter in cultured SMCs in response to hypoxia with or without POVPC versus normoxia with or without POVPC. The schematics represent the Oct4 promoter region (from −250 bp to +50 bp) relative to the transcriptional start site, indicated with arrows (see Supplementary Fig. 11 for more details).
Open a similar mechanism. This mechanism would not be detected through bisulfite sequencing, which does not distinguish between 5-methylcytosine (5-mC) and 5-hydroxymethylcytosine (5-hmC). To test this possibility, and to ensure that the results are relevant to Oct4 reactivation within lesions in vivo, we elected to first assess the global levels of DNA hydroxymethylation in the Oct4 locus using DNA isolated from the aortic arch regions of Apoe −/− mice fed a Western diet for 20 weeks. We found significant increases in 5-hmC content at four separate regions across the Oct4 promoter in these mice, as compared to chow-diet-fed Apoe +/+ mice (Fig. 5b, Supplementary  Fig. 11 and Supplementary Table 3 ).
To determine whether DNA hydroxymethylation of the Oct4 locus occurs in SMCs, we assessed 5-hmC enrichment at the Oct4 promoter in SMCs exposed to hypoxia and/or the toll-like receptor 3 (TLR3) agonist polyinosinic:polycytidylic acid (poly(I:C)).
Our rationale for using poly(I:C) was fourfold. First, the combination of hypoxia and inflammatory stimuli better mimics the complexity of the environmental cues within atherosclerotic lesions; second, TLR3 signaling is activated within SMCs in atherosclerotic lesions 36, 37 ; third, recent observations have demonstrated that TLR3 activation facilitates iPSC reprogramming 38 ; and fourth, poly(I:C) treatment resulted in the activation of Oct4 and the downregulation of Acta2 in cultured SMCs (Fig. 5c) . We found that both hypoxia and poly(I:C) treatment of cultured SMCs induced increases in 5-hmC content at the Oct4 promoter ( Fig. 5d) . Finally, we demonstrated that SMCs within atherosclerotic lesions exhibited DNA hydroxymethylation at the Oct4 promoter by performing ISH-PLA 23 npg including both ACTA2 − YFP + and ACTA2 + YFP + SMCs, was evident within the tunica media and atherosclerotic lesions of SMC YfP +/+ Apoe −/− mice (Fig. 5e) .
We conducted further mechanistic analyses of Oct4 transcriptional activation in SMCs during phenotypic switching by testing the roles of the transcription factors KLF4 and HIF-1α, as the Oct4 proximal promoter contains conserved binding sites for both factors (Supplementary Fig. 11) , and expression of KLF4 and HIF-1α have been previously reported in phenotypically modulated SMCs 27, 39, 40 . Overexpression of KLF4 in cultured SMCs markedly increased the expression of Oct4 (Fig. 6a) , whereas Oct4 expression was decreased in Klf4-deficient SMCs in response to POVPC relative to Klf4 +/+ SMCs (Fig. 6b) . Moreover, KLF4 and HIF-1α were enriched at the Oct4 gene promoter in cultured SMCs treated with POVPC ( Fig. 6c ). Next, we tested the involvement of consensus KLF4 and HIF-1α binding sites for the activation of Oct4 transcription in cultured aortic SMCs. POVPC and oxLDL induced the transcriptional activity of a 1.5-kb Oct4 promoter-luciferase construct by five-and threefold respectively, and these effects were completely abolished by mutation in either the KLF4 or the HIF-1α binding sites (Fig. 6d,e) . The activation of Oct4 by oxLDL via HIF-1α-dependent mechanisms is of particular interest, because it has been shown that oxLDL can activate HIF-1α even under normoxic conditions 41 . We also showed that KLF4 and HIF-1α were enriched at the Oct4 gene promoter, on the basis of ChIP analyses of chromatin isolated from blood vessels of Apoe −/− mice after 18 weeks of feeding with a high-fat Western diet, as compared to control Apoe +/+ mice fed a chow diet (Fig. 6f,g) . Finally, we detected KLF4 binding to the Oct4 promoter in YFP + cells within SMC YfP +/+ Apoe −/− atherosclerotic lesions in vivo by ISH-PLA (Fig. 6h) . Taken together, these data provide compelling evidence that the reactivation of Oct4 within SMCs in the setting of atherosclerosis involves combinatorial effects of pro-inflammatory signaling (i.e., TLR3 activation), hypoxia, and oxidized phospholipids, as well as epigenetic mechanisms mediated through DNA hydroxymethylation.
DISCUSSION
Our results indicate that the knockout of Oct4 in SMCs of Apoe −/− Western-diet-fed mice results in multiple functional changes that directly or indirectly contribute to an increase in lesion pathogenesis, including a reduction in the number of SMCs within lesions and impairment in the formation of a protective fibrous cap, as well as increased expression of multiple pro-inflammatory genes. OCT4 thus seems to promote an atheroprotective SMC phenotype, given that its loss results in lesions that are larger than OCT4 wild-type lesions and that exhibit features consistent with reduced plaque stability and/or exacerbated pathogenesis.
These findings provide the first evidence, to our knowledge, of a functional role for the pluripotency factor OCT4 in somatic cells. Paradoxically, SMC-specific loss of Oct4, as compared to SMC-specific loss of Klf4, has virtually completely opposite overall effects on lesion pathogenesis, as reported in recent studies by our lab 18 : Klf4 loss results in smaller and more stable lesions than those caused by Oct4 loss, which results in larger and less stable lesions. To explain these effects, we postulate that KLF4 and OCT4 have rate-limiting roles in controlling highly different aspects of SMC phenotypic transitions. Loss of Oct4 in SMCs seems to affect a very early stage in the phenotypic transitions of SMCs, which leads to a marked impairment of SMC migration from the medial layer into lesions and results in lesions that virtually lack a fibrous cap and that exhibit numerous features of plaque destabilization. By contrast, loss of Klf4 in SMCs is not associated with a decrease in the number of SMCs within lesions, probably owing to compensatory gene activation (see below). However, loss of Klf4 in SMCs is associated with marked alterations in the nature of SMC phenotypic transitions, leading to a >60% decrease in the number of SMC-derived, macrophage-like proinflammatory foam cells, as compared to Klf4 +/+ mice, but to an increase in the number of ACTA2 + SMCs that invest into the fibrous cap, and to overall changes consistent with plaque stabilization 18 . A cartoon modeling the differential effects of SMC-specific loss of Klf4 versus Oct4 is shown in Supplementary Figure 12. Taken together, these studies further highlight the crucial overall role that SMCs have in lesion pathogenesis. However, the effects of SMCs on lesions can be beneficial or detrimental, depending on the nature of the phenotypic transitions.
Intriguingly, although KLF4 and OCT4 have different roles in SMC phenotypic transitions, we found that KLF4 seems to regulate Oct4 expression in SMCs in vitro and in vivo. One possibility to account for these findings is that increased expression of Klf2, Klf5, or other genes may compensate for the loss of Klf4, with regard to Oct4 activation and subsequent regulation of early stages of SMC phenotypic transitions. This hypothesis would be consistent with our studies showing that SMC numbers are not reduced in SMC-specific Klf4 knockout mice 18 , as well as with studies showing that KLF4 is dispensable for iPSC reprogramming 42 . Indeed, given that phenotypic plasticity of this cell is essential for vessel repair and remodeling throughout life, there are likely to be redundant pathways for the activation of Oct4 in SMCs. Another, not mutually exclusive, possibility is that the regulation of Oct4 reactivation in somatic cells is much more complex than simply the binding of KLF4 to the Oct4 promoter, and this regulation is likely to vary extensively under physiological and pathological conditions.
Crucial challenges for future studies will be: first, to determine whether OCT4 is reactivated and has a role in regulating the plasticity of other somatic cell types in the setting of disease or injury repair; second, to define the role of OCT4 in SMCs in the context of different cardiovascular diseases, including hypertension, myocardial infarction, and arterial aneurysms, as well as in vascular remodeling in the setting of tissue repair and tumor growth; third, to further define the mechanisms and factors that reactivate Oct4 within somatic cells, including elucidation of the role of epigenetic regulation; and, fourth, to identify mechanisms and factors that regulate the nature of SMC phenotypic transitions within advanced lesions, with the goal of identifying pathways or therapeutic targets that promote plaque stabilization.
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